We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    ivermectin | COVID-19 | Oxford
Previous Study | Return to List | Next Study

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PLATCOV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05041907
Recruitment Status : Recruiting
First Posted : September 13, 2021
Last Update Posted : September 8, 2022
Sponsor:
Information provided by (Responsible Party):
University of Oxford

Brief Summary:

The trial will develop and validate a platform for quantitative assessment of antiviral effects in low-risk patients with high viral burdens and uncomplicated

COVID-19 to determine in-vivo antiviral activity. In this randomized open label, controlled, group sequential adaptive platform trial, we will assess the performance of three distinct types of intervention relative to control (no treatment):

A: Newly available and repurposed potential antiviral drugs; B: Positive control: monoclonal antibodies initially but subsequently any therapeutic that is shown to accelerate the rate of viral clearance C: Novel small molecule drugs that have gone through phase 1 testing

PLATCOV study is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator.


Condition or disease Intervention/treatment Phase
COVID-19 Drug: Favipiravir Drug: Monoclonal antibodies Drug: Ivermectin Other: No treatment Drug: Remdesivir Drug: Fluoxetine Drug: Molnupiravir Drug: Nirmatrelvir/ritonavir (e.g. PAXLOVID™) Drug: Nitazoxanide Phase 2

Detailed Description:

The platform trial will assess drugs with potential SARS-CoV-2 antiviral

Activity of three general types:

A. Newly available and repurposed potential antiviral drugs. (initially from: hydroxychloroquine, ivermectin, lopinavir-ritonavir, miglustat, remdesivir, nitazoxanide, nebulized unfractionated heparin (UFH), favipiravir, Molnupiravir, Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Fluoxetine, Fluvoxamine, AZD7442 (Evusheld),ensitrelvir, and a combination of Molnupiravir and Nirmatrelvir/ritonavir (e.g. PAXLOVID™)

Newly available and repurposed drugs are already used and recommended in some countries. Showing that they do not have significant antiviral activity is as important as showing that they do. For the newly approved antivirals, comparing antiviral activities in- vivo will inform health authorities' recommendations.

B. Positive control: monoclonal antibodies initially (e.g. casirivimab/imdevimab) but subsequently any therapeutic that is shown to accelerate the rate of viral clearance

Monoclonal antibodies are vulnerable to viral escape mutations. Tracking their performance over time is important to characterise the impact and inform the therapeutics of mutant SARS-CoV-2 strains. This will also be important for other antivirals. Monoclonal antibodies are expensive and cannot be produced at large scale currently, but this may change in the near future. These drugs may not be available early in the study, and will be included if there is local availability and regulatory approval.

C. Novel small molecule drugs that have gone through phase 1 testing Each site will include a negative control arm consisting of patients not receiving any study drug except for antipyretics- paracetamol. At any given time in the study, it is possible that not all intervention arms are available.

Randomization to the no antiviral treatment control arm (no intervention) will be fixed at a minimum of 20% throughout the study. The randomization ratios will be uniform for all available interventions.

Recruitment onto the ivermectin arm was stopped on April 18th 2022 due to meeting the pre- defined stopping criteria.

Recruitment onto the remdesivir arm was stopped on June 10th 2022 due to meeting the pre- defined stopping criteria.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
Actual Study Start Date : September 30, 2021
Estimated Primary Completion Date : August 2024
Estimated Study Completion Date : August 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Positive control (monoclonals) Drug: Monoclonal antibodies
Monoclonal antibodies: 600mg casirivimab/ 600mg imdevimab given once on D0

Experimental: Favipiravir Drug: Favipiravir
Favipiravir 1800mg BD D0 and 800mg BD for a further 6/7.

Experimental: Ivermectin
[This arm is now closed to recruitment]
Drug: Ivermectin
Ivermectin 600micrograms/kg/day for 7/7.

Experimental: Remdesivir
[This arm is now closed to recruitment]
Drug: Remdesivir
Remdesivir 200mg D0 and 100mg for a further 4/7.

Negative control group Other: No treatment
No treatment (except antipyretics- paracetamol)

Experimental: Fluoxetine Drug: Fluoxetine
Fluoxetine 40mg OD for 7/7

Experimental: Molnupiravir Drug: Molnupiravir
Molnupiravir 800mg BD for 5/7

Experimental: Nirmatrelvir/ritonavir (e.g. PAXLOVID™) Drug: Nirmatrelvir/ritonavir (e.g. PAXLOVID™)
Nirmatrelvir 300mg BD for 5/7 Ritonavir 100mg BD for 5/7

Experimental: Nitazoxanide Drug: Nitazoxanide
Nitazoxanide 1.5g BD 7/7




Primary Outcome Measures :
  1. Rate of viral clearance for newly available and repurposed drugs [ Time Frame: Days 0-7 ]
    Rate of viral clearance- estimated from the log10 viral density derived from qPCR of standardised duplicate oropharyngeal swabs/ saliva taken daily from baseline (day 0) to day 7 for each newly available and repurposed drug compared with the no antiviral treatment control i.e. those not receiving study drug

  2. Rate of viral clearance for positive controls (e.g. monoclonal antibodies) [ Time Frame: Days 0-7 ]
    Rate of viral clearance- estimated from the log10 viral density derived from qPCR of standardised duplicate oropharyngeal swabs/ saliva taken daily from baseline (day 0) to day 7 for positive controls (e.g. monoclonal antibodies) compared with the no antiviral treatment control i.e. those not receiving study drug

  3. Rate of viral clearance for small novel molecule drugs [ Time Frame: Days 0-7 ]
    Rate of viral clearance- estimated from the log10 viral density derived from qPCR of standardised duplicate oropharyngeal swabs/ saliva taken daily from baseline (day 0) to day 7 for small novel molecule drugs compared with the no antiviral treatment control i.e. those not receiving study drug


Secondary Outcome Measures :
  1. Viral kinetic levels in early COVID-19 disease [ Time Frame: Days 0-7 ]
    Rate of viral clearance- estimated from the log10 viral density derived from qPCR of standardised duplicate oropharyngeal swabs/ saliva taken daily from baseline (day 0) to day 7 for each therapeutic arm compared with the no antiviral treatment control i.e. those not receiving study drug

  2. Number of antiviral treatment arms that are shown to be effective i.e. a positive signal (>90% probability of >12.5% acceleration in viral clearance) [ Time Frame: Days 0-7 ]
    Rate of viral clearance- estimated from the log10 viral density derived from qPCR of standardised duplicate oropharyngeal swabs/ saliva taken daily from baseline (day 0) to day 7 for each therapeutic arm compared with the no antiviral treatment control i.e. those not receiving study drug

  3. Rates of viral clearance by treatment arm, as compared against REGN-COV2 (monoclonal antibody cocktail) monoclonal antibody cocktail) or other licensed and available therapeutics with evidence of accelerated viral clearance(monoclonal antibody cocktail) [ Time Frame: Days 0-7 ]
    Rate of viral clearance- estimated from the log10 viral density derived from qPCR of standardised duplicate oropharyngeal swabs/ saliva taken daily from baseline (day 0) to day 7 for each therapeutic arm compared with positive control (e.g. REGN-COV-2 a monoclonal antibody cocktail) or other licensed and available therapeutics with evidence of accelerated viral clearance.


Other Outcome Measures:
  1. Rates of hospitalisation by treatment arm (hospitalisation for clinical reasons) [ Time Frame: Days 0-28 ]
    Number of hospitalisations up to Day 28 in a treatment arm with an increased rate of viral clearance compared with the negative control i.e. patients not receiving study drug



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient understands the procedures and requirements and is willing and able to give informed consent for full participation in the study.
  • Previously healthy adults, male or female, aged 18 to 50 years at time of consent with early symptomatic COVID-19
  • SARS-CoV-2 positive by lateral flow antigen test OR a positive PCR test for SARS-CoV-2 within the last 24hrs with a Ct value of less than 25 (all viral targets)
  • Symptoms of COVID-19 (including fever, or history of fever) for less than 4 days (96 hours).
  • Oxygen saturation ≥96% measured by pulse-oximetry at time of screening.
  • Able to walk unaided and unimpeded in ADLs
  • Agrees and is able to adhere to all study procedures, including availability and contact information for follow-up visits

Exclusion Criteria:

The patient may not enter the study if ANY of the following apply:

  • Taking any concomitant medications or drugs (see appendix 4)†
  • Presence of any chronic illness/ condition requiring long term treatment, or other significant comorbidity (e.g. diabetes, obesity but see appendix 4 for the full list)
  • Laboratory abnormalities discovered at screening (see appendix 4)
  • For females: pregnancy, actively trying to become pregnant, or lactation
  • Contraindication to taking, or known hypersensitivity reaction to any of the proposed therapeutics (see appendix 4)
  • Currently participating in another COVID-19 therapeutic or vaccine trial
  • Evidence of pneumonia (although imaging is NOT required)

    • healthy women on the oral contraceptive pill are eligible to join the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05041907


Contacts
Layout table for location contacts
Contact: William Schilling, MD +662 203 6333 william@tropmedres.ac
Contact: Nicholas J White, Prof. +662 203 6333 nickw@tropmedres.ac

Locations
Layout table for location information
Brazil
Universidade Federal de Minas Gerais Recruiting
Minas Gerais, Brazil
Contact: Mauro Martins Teixeira       mmtex.ufmg@gmail.com   
Thailand
Vajira hospital Terminated
Bangkok, Thailand, 10300
Faculty of Tropical Medicine, Mahidol University Recruiting
Bangkok, Thailand, 10400
Contact: Weerapong Phumratanaprapin, MD       weerapong.phu@mahidol.ac.th   
Bangplee Hospital Terminated
Samut Prakan, Thailand, 10540
Sponsors and Collaborators
University of Oxford
Layout table for additonal information
Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT05041907    
Other Study ID Numbers: VIR21001
First Posted: September 13, 2021    Key Record Dates
Last Update Posted: September 8, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

With patient's consent, clinical data and results from blood analyses stored in the database may be shared according to the terms defined in the MORU data sharing policy with other researchers to use in the future.

Data generated from this study will adhere to the 2016 "Statement on data sharing in public health emergencies"(https://wellcome.ac.uk/press-release/statement-data-sharing-public-health-emergencies).

Supporting Materials: Clinical Study Report (CSR)
Analytic Code
Time Frame: after the main paper has been published
Access Criteria:

MORU Data Sharing Policy https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/data-sharing.

The criteria for authorship will be consistent with the international guidelines (http://www.icmje.org/#author).

URL: http://wellcome.ac.uk/press-release/statement-data-sharing-public-health-emergencies

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Oxford:
COVID-19
Phase 2
Antiviral Pharmacodynamics
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Ivermectin
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Ritonavir
Nitazoxanide
Remdesivir
Favipiravir
Fluoxetine
Antibodies
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
HIV Protease Inhibitors
Viral Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents